Infeksjonsrisiko ved bruk av selektivt immunmodulerende midler mot revmatoid artritt

Tidsskrift for den Norske Laegeforening

Volumn 132, Issue 16, 2012, Pages 1867-1871

  Harboe, Erna ^a   Damås, Jan Kristian ^b   Omdal, Roald ^a   Frøland, Stig S ^c   Sjursen, Haakon ^d  

^a Stavanger universitetssjukehus ^*  (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION; PHYSIOLOGY; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; TUBERCULOSIS; VIRUS ACTIVATION;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFECTION; RISK ASSESSMENT; RISK FACTORS; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA; VIRUS ACTIVATION;

EID: 84867678320     PISSN: 00292001     EISSN: 08077096     Source Type: Journal    
DOI: 10.4045/tidsskr.12.0180     Document Type: Article

References (40)

1. Gullick NJ, Scott DL. Co-morbidities in established rheumatoid arthritis. Best Pract Res Clin Rheumatol 2011; 25: 469-83.
2. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987; 30: 1205-13.
3. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001; 344: 907-16.
4. Gjersvik P, Bretthauer M. Unngå biologiske legemidler. Tidsskr Nor Legeforen 2010; 130: 1846-7.
5. Doran MF, Crowson CS, Pond GR et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002; 46: 2287-93.
6. Mutru O, Laakso M, Isomäki H et al. Ten year mortality and causes of death in patients with rheumatoid arthritis. Br Med J (Clin Res Ed) 1985; 290: 1797-9.
7. Doran MF, Crowson CS, Pond GR et al. Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002; 46: 2294-300.
8. Bendtzen K, Geborek P, Svenson M et al. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum 2006; 54: 3782-9.
9. Dixon WG, Watson K, Lunt M et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006; 54: 2368-76.
10. Wallis RS, Broder MS, Wong JY et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004; 38: 1261-5.
11. Winthrop KL, Yamashita S, Beekmann SE et al. Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the Emerging Infections Network. Clin Infect Dis 2008; 46: 1738-40.
12. Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098-104.
13. Wallis RS, Broder M, Wong J et al. Granulomatous infections due to tumor necrosis factor blockade: correction. correction. Clin Infect Dis 2004; 39: 1254-5.
14. Co DO, Hogan LH, Kim SI et al. Mycobacterial granulomas: keys to a long-lasting host-pathogen relationship. Clin Immunol 2004; 113: 130-6.
15. Listing J, Strangfeld A, Kary S et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005; 52: 3403-12.
16. Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 2009; 68: 1136-45.
17. Singh JA, Wells GA, Christensen R et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011; 2: CD008794.
18. Calabrese LH, Zein NN, Vassilopoulos D. Hepatitis B. virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis 2006; 65: 983-9.
19. Tamori A, Koike T, Goto H et al. Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts. J Gastroenterol 2011; 46: 556-64.
20. Vassilopoulos D, Apostolopoulou A, Hadziyannis E et al. Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis 2010; 69: 1352-5.
21. Edwards JC, Szczepanski L, Szechinski J et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350: 2572-81.
22. Cohen SB, Emery P, Greenwald MW et al. Rituximab for rheumatoid arthritis refractory to antitumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54: 2793-806.
23. Emery P, Fleischmann R, Filipowicz-Sosnowska A et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006; 54: 1390-400.
24. van Vollenhoven RF, Emery P, Bingham CO 3rd et al. Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol 2010; 37: 558-67.
25. Pyrpasopoulou A, Douma S, Vassiliadis T et al. Reactivation of chronic hepatitis B virus infection following rituximab administration for rheumatoid arthritis. Rheumatol Int 2011; 31: 403-4.
26. Carson KR, Evens AM, Richey EA et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009; 113: 4834-40.
27. Furst DE. The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum 2010; 39: 327-46.
28. Smitten AL, Choi HK, Hochberg MC et al. The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol 2008; 35: 387-93.
29. Pizzo PA. Fever in immunocompromised patients. N Engl J Med 1999; 341: 893-900.
30. Salliot C, Dougados M, Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: metaanalyses of randomised placebo-controlled trials. Ann Rheum Dis 2009; 68: 25-32.
31. Cabanillas F, Liboy I, Pavia O et al. High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication. Ann Oncol 2006; 17: 1424-7.
32. Fluge O, Bruland O, Risa K et al. Benefit from Blymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A doubleblind and placebo-controlled study. PLoS ONE 2011; 6: e26358.
33. Folkehelseinstituttet. Behandling med TNF-alfablokkere og risiko for tuberkulose-råd om vurdering, forebygging og behandling. Forebygging og kontroll av tuberkulose. Supplement til smittevern nr. 7/2007. www.fhi.no/dav/38ad33caf5.pdf (3.7.2012).
34. Folkehelseinstituttet. Anbefalinger for bruk av Interferon-gamma Release Assays (IGRA) ved diagnostikk av tuberkulose i Norge. www.fhi.no/dav/cecea2b2f2.pdf (3.7.2012).
35. Buch MH, Smolen JS, Betteridge N et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2011; 70: 909-20.
36. Brunasso AM, Puntoni M, Gulia A et al. Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review. Rheumatology (Oxford) 2011; 50: 1700-11.
37. Ghany MG, Strader DB, Thomas DL et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-74.
38. Keyser FD. Choice of biologic therapy for patients with rheumatoid arthritis: The infection perspective. Curr Rheumatol Rev 2011; 7: 77-87.
39. UpToDate. Acute phase reactants. www.uptodate.com/contents/acute-phasereactants? source=search_result&search=crp+ infection&selectedTitle=1%7E150#H14 (3.7.2012).
40. Askling J, Fored CM, Brandt L et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 2007; 66: 1339-44.